Metabolic Research

Tirzepatide + AOD-9604 Stack — GLP-1 Weight Loss Peptide Stack Research

Pairs one GLP-1 class compound with a non-GLP-1 lipolytic fragment. Only one GLP-1 is ever included — never Tirzepatide with Semaglutide or Retatrutide.

Total program: 12 weeks · 2 individual vials

Why these peptides are researched together

Tirzepatide and AOD-9604 act through unrelated pathways. Tirzepatide activates GIP and GLP-1 receptors, which govern appetite and insulin signaling. AOD-9604 is a modified fragment of growth hormone (176–191) studied for fat breakdown (lipolysis) without raising IGF-1. The pairing combines an appetite and insulin pathway with a fat-cell pathway.

Each peptide at a glance

How the schedules fit together

One weekly, one daily: Tirzepatide is drawn once per week on a fixed day and steps up every 4 weeks on its chart; AOD-9604 is drawn once daily, usually in the morning. Both run the full 12-week program. The two are kept in separate syringes because GLP-1 formulations are generally not mixed with other compounds.

What the research shows

Tirzepatide alone has strong randomized-trial evidence (SURMOUNT program).

Still unproven

AOD-9604 human evidence is limited, and no trial has tested this combination.

FAQs

What is the Tirzepatide + AOD-9604 Stack?

Pairs one GLP-1 class compound with a non-GLP-1 lipolytic fragment. Only one GLP-1 is ever included — never Tirzepatide with Semaglutide or Retatrutide.

What's in the Tirzepatide + AOD-9604 Stack?

The Tirzepatide + AOD-9604 Stack combines Tirzepatide and AOD-9604, each in its own vial. Tirzepatide: Dual GIP/GLP-1 receptor agonist with large published clinical trials. AOD-9604: Modified hGH fragment 176–191 studied in lipolysis models.

What does the Tirzepatide + AOD-9604 Stack do?

Tirzepatide and AOD-9604 act through unrelated pathways. Tirzepatide activates GIP and GLP-1 receptors, which govern appetite and insulin signaling. AOD-9604 is a modified fragment of growth hormone (176–191) studied for fat breakdown (lipolysis) without raising IGF-1. The pairing combines an appetite and insulin pathway with a fat-cell pathway.

What is the Tirzepatide + AOD-9604 Stack dosage?

The amounts for each peptide are listed week by week in the dosing table on this page, taken from each peptide's full dosing chart, with units on a 100-unit syringe and exact vial counts for the full 12-week program.

How long is the Tirzepatide + AOD-9604 Stack?

The Tirzepatide + AOD-9604 Stack is laid out as a 12-week research program. One weekly, one daily: Tirzepatide is drawn once per week on a fixed day and steps up every 4 weeks on its chart; AOD-9604 is drawn once daily, usually in the morning. Both run the full 12-week program. The two are kept in separate syringes because GLP-1 formulations are generally not mixed with other compounds.

What does research show about the Tirzepatide + AOD-9604 Stack?

Tirzepatide alone has strong randomized-trial evidence (SURMOUNT program). Still unproven: AOD-9604 human evidence is limited, and no trial has tested this combination.

Sources

Other peptide stacks

Educational research reference only. Not medical advice or individualized guidance.